Novel Small Molecule Drugs for the Treatment of Triple-Class Refractory Myeloma
September 29th 2021Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
Read More
Phase 3 Study of Coadministration of Seasonal Flu Vaccine With Prevnar 20 Shows Promising Results
September 29th 2021The researchers noted the importance of maintaining vaccination rates for conditions that can lead to respiratory issues, especially with COVID-19 cases still raising concern throughout the United States.
Read More